CompletedPhase 2

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

United States51 participantsStarted 2006-05

Plain-language summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV Hodgkin's lymphoma.

Who can participate

Age range18 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed classical Hodgkin's lymphoma * No lymphocyte-predominant histology * Stage II, III, or IV disease * Newly diagnosed disease PATIENT CHARACTERISTICS: * Performance status 0-2 * Creatinine \< 2.0 mg/dL * Bilirubin \< 5 mg/dL * Not pregnant or nursing * No HIV positivity * Hepatitis B surface antigen negative * No active concurrent malignancy except for superficial nonmelanoma skin cancer or cervical carcinoma in situ PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy for Hodgkin's lymphoma * Steroids allowed if medically required before chemotherapy initiation

What they're measuring

Effect of Rituximab on EBV(+) Tumors

Timeframe: Up to 56 months

Relationship Between Marker Detection and Clinical Outcome

Timeframe: 3 years

Trial details

NCT IDNCT00369681

SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-10

Results submitted2015-05-20